Effect of WF10 (Immunokine) on Diabetic Foot Ulcer Therapy: A Double-blind, Randomized, Placebo-controlled Trial

Journal of Foot and Ankle Surgery

Volumn 50, Issue 6, 2011, Pages 635-640

  Yingsakmongkol, Narongchai ^a   Maraprygsavan, Paiboon ^b   Sukosit, Phongthon ^b  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b POLICE GENERAL HOSPITAL   (Thailand)

Author keywords

Diabetes mellitus; Foot ulcer; Inflammation; Surgery; TCDO; Wound

Indexed keywords

IMMUNOKINE; PLACEBO; TETRACHLORODECAOXIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRANULATION TISSUE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INFLAMMATION; SKIN NECROSIS; THROMBOPHLEBITIS; TREATMENT OUTCOME; WOUND ASSESSMENT; WOUND INFECTION;

AGED; CHLORINE; COMBINED MODALITY THERAPY; DEBRIDEMENT; DIABETIC FOOT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRANULATION TISSUE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXIDES; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SKIN CARE; TREATMENT OUTCOME; WOUND HEALING;

EID: 80054957456     PISSN: 10672516     EISSN: 15422224     Source Type: Journal    
DOI: 10.1053/j.jfas.2011.05.006     Document Type: Article

References (37)

1. International Diabetes Federation. The Global Burden. In: IDF Diabetes Atlas, 4th ed, Brussels, Belgium, International Diabetes Federation, 2009. Available from: Accessed April 21, 2010. http://www.diabetesatlas.org.
2. Aekplakorn W., Abbot-Klafter J., Premgamone A., Dhanamun B., Chaikittiporn C., Chongsuvivatwong V., Suwanprapisa T., Chaipornsupaisan W., Tiptaradol S., Lim S.S. Prevalence and management of diabetes and associated risk factors by regions of Thailand: Third National Health Examination Survey 2004. Diabetes Care 2007, 30:2007-2012.
3. Palumbo PJ, Melton LJI. Peripheral vascular disease and diabetes. In: Diabetes in America. 2nd ed, pp 401-8, edited by National Diabetes Data Group, Washington DC, Government Printing Office, 1995.
4. International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot, Amsterdam, John Wiley & Sons, pp 1-96, 1999.
5. Deerochanawong C., Home P.D., Alberti K.G.M.M. A survey of lower limb amputation in diabetic patients. Diabet Med 1992, 9:942-946.
6. Mayfield J.A., Reiber G.E., Maynard C., Czerniecki J.M., Caps M.T., Sangeorzan B.J. Trends in lower limb amputation in the Veterans Health Administration, 1989-1998. J Rehabil Res Dev 2000, 37:23-30.
7. Pecoraro R.E., Ahroni J.H., Boyko E.J., Stensel V.L. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes Care 1991, 40:1305-1313.
8. Jonsson K., Jensen J.A., Goodson W.H., Scheuenstuhl H., West J., Hopf H.W., Hunt T.K. Tissue oxygenation, anemia, and perfusion in relation to wound healing in surgical patients. Ann Surg 1991, 214:605-613.
9. Matsen F.A., Wyss C.R., Pedegana L.R., Krugmire R.B., Simmons C.W., King R.V., Burgess E.M. Transcutaneous oxygen tension measurement in peripheral vascular disease. Surg Gynecol Obstet 1980, 150:525-528.
10. McMahon M.M., Bistrian B.R. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995, 9:1-10.
11. Leibovich S.J., Ross R. The role of the macrophage in wound repair: a study with hydrocortisone and antimacrophage serum. Am J Pathol 1975, 78:71-100.
12. DiPietro L.A. Wound healing: the role of macrophage and other immune cells. Shock 1995, 4:233-240.
13. Reiber G.E., Pecoraro R.E., Koepsell T.D. Risk factors for amputation in patients with diabetes mellitus: a case control study. Ann Intern Med 1992, 117:97-105.
14. Veerasarn V., Khorprasert C., Lorvidhaya V., Sangruchi S., Tantivatana T., Narkwong L., Kongthanarat Y., Chitapanarux I., Tesavibul C., Panichevaluk A. Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomised, two-arm, open-label trial. Radiother Oncol 2004, 73:179-185.
15. Veerasarn V., Boonnuch W., Kakanaporn C. A phase II study to evaluate WF10 in patients with late hemorrhagic radiation cystitis and proctitis. Gynecol Oncol 2006, 100:179-184.
16. Penpattanagul S. Reduced incidence and severity of acute radiation mucositis by WF10 (Immunokine®) as adjunct to standard of cure in the management of head & neck cancer patients. J Med Assoc Thai 2007, 90:1590-1600.
17. Raffanti S.P., Schaffner W., Federspiel C.F., Blackwell R.B., Ching O.A., Kühne F.W. Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection 1998, 26:201-206.
18. Dühmke E. Radiation treatment in advanced malignant tumors under the influence of the oxidant tetrachlorodecaoxygen anion (TCDO)-a pilot study. Reaktive Sauerstoffspezies in der Medizin 1986, 238-246. Springer Verlag, Berlin. E.F. Elstner, W. Bors, W. Wilmanns (Eds.).
19. Gillissen G., Kühne F.W., Breuer-Werle M., Melzer B., Ostendorp H. Increased resistance towards two systemic experimental infections by tetrachlorodecaoxygen anion complex (TCDO): possible implications of cellular and humoral immunity. Arzneimittelforschung 1986, 36:1778-1782.
20. Woerly G., Lombard Y., Poindron P., Stahl K.W. Candida phagocytosis of murine macrophages: enhancement by a novel type of oxidant. Adv Biosci 1987, 66:109-112.
21. Hinz H., Hautzinger H., Stahl K.W. Rationale for and results from a randomised double-blind trial of tetrachlorodecaoxygen anion complex in wound healing. Lancet 1986, 12:825-828.
22. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. pp 191-205, edited by CM McLeod, Columbia University Press, New York, 1949.
23. Wagner FW Jr. A classification and treatment program for diabetic, neuropathic, and dysvascular foot problems. In: Instructional Course Lectures: The American Academy of Orthopaedic Surgeons. vol 28, p 143-65, St Louis, Mosby, 1979.
24. Lavery L.A., Armstrong D.G., Murdoch D.P., Peters E.J.G., Lipsky B.A. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis 2007, 44:562-565.
25. Baranoski S, Ayello EA. Wound assessment. In: Wound care essentials: Practice principle. 2nd ed, pp 77-92. Philadelphia, Lippincott Williams & Wilkins, 2008.
26. Sheehan P., Jones P., Caselli A., Giurini J.M., Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003, 26:1879-1882.
27. Oyibo S.O., Jude E.B., Tarawneh I., Nguyen H.C. The effects of ulcer size and site, patients' age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001, 18:133-138.
28. Langemo D.K., Melland H., Hanson D., Olson B., Hunter S., Henly S.J. Two-dimensional wound measurement: comparison of 4 techniques. Adv Skin Wound Care 1998, 11:337-343.
29. International Diabetes Federation. Diabetes and foot care: Time to act, pp 1-198, Brussels, IDF Publications, 2005.
30. Smiell J.M., Wieman T.J., Steed D.L., Perry B.H., Sampson A.R., Schwab B.H. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999, 7:335-346.
31. Baranoski S, Ayello EA. Wound treatment options. In: Wound care essentials: Practice principle, 2nd ed, pp 136-71. edited by S Baranoski, EA Ayello, Philadelphia, Lippincott Williams & Wilkins, 2008.
32. Oriani G., Meazza D., Favales F., Pizzi G., Aldeghi A., Faglia E. Hyperbaric oxygen therapy in diabetic gangrene. J Hyperb Med 1990, 5:171-175.
33. Badiavas E.V., Falanga V. Gene therapy. J Dermatol 2001, 28:175-192.
34. Gentzkow G.D., Iwasaki S.D., Hershon K.S., Mengel M., Prendergast J.J., Ricotta J.J., Steed D.P., Lipkin S. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996, 19:350-354.
35. Giese T., McGrath M.S., Stumm S., Schempp H., Elstner E.F., Meuer S.C. Differential effects on innate versus adaptive immune responses by WF10. Cell Immunol 2004, 229:149-158.
36. Schempp H., Reim M., Dornisch K., Elstner E.F. Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF10. Arzneimittelforschung 2001, 51:554-562.
37. Klamt F., Shacter E. Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage. J Biol Chem 2005, 280:21346-21352.